Role of valproate across the ages. Treatment of epilepsy in the elderly

Acta Neurologica Scandinavica

Volumn 114, Issue SUPPL. 184, 2006, Pages 28-37

  Perucca, E ^a   Aldenkamp, A ^b,c   Tallis, R ^d   Kramer G ^e  

^a UNIVERSITY OF PAVIA   (Italy)

^b EPILEPSY CENTER KEMPENHAEGHE   (Netherlands)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

^e SWISS EPILEPSY CENTER   (Switzerland)

Author keywords

Elderly; Epilepsy; Treatment; Valproate

Indexed keywords

ACETYLSALICYLIC ACID; CARBAMAZEPINE; ETIRACETAM; FELBAMATE; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PREGABALIN; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE; CYTOCHROME P450;

ACCIDENT PRONENESS; ACCIDENTAL INJURY; AGED; BEHAVIOR DISORDER; BONE ATROPHY; BONE FRAGILITY; BRAIN DISEASE; CARDIOTOXICITY; CEREBROVASCULAR ACCIDENT; COMORBIDITY; COMPLEX PARTIAL SEIZURE; CONSENSUS DEVELOPMENT; DEPRESSION; DIAGNOSTIC ERROR; DOSE CALCULATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG METABOLISM; DRUG MONITORING; DRUG TOLERABILITY; EPILEPSY; EPILEPTOGENESIS; FOCAL EPILEPSY; FRAGILITY FRACTURE; GASTROINTESTINAL SYMPTOM; GENERALIZED EPILEPSY; GERIATRIC PATIENT; HUMAN; HYPOGLYCEMIA; HYPONATREMIA; IRRITABILITY; LIVER DYSFUNCTION; MEMORY DISORDER; MENTAL DISEASE; MOOD DISORDER; MOTOR DYSFUNCTION; NERVE DEGENERATION; NEUROTOXICITY; ORGANIC BRAIN SYNDROME; PARKINSONISM; PLASMA PROTEIN BINDING; PRACTICE GUIDELINE; REVIEW; RISK FACTOR; SEDATION; SEIZURE; SIDE EFFECT; STROKE; SYNCOPE; TERATOGENICITY; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTOPENIA; TRANSIENT GLOBAL AMNESIA; TRANSIENT ISCHEMIC ATTACK; TREATMENT INDICATION; TREMOR; WEIGHT GAIN; DRUG CONTRAINDICATION; DRUG INTERACTION; DRUG TOLERANCE; METABOLISM; MIDDLE AGED;

AGED; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; DRUG TOLERANCE; EPILEPSY; HUMANS; MIDDLE AGED; VALPROIC ACID;

EID: 33745077081     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2006.00668.x     Document Type: Review

References (57)

1. Loiseau J Loiseau P Duche B Guyot M Dartigues JF Aublet B. A survey of epileptic disorders in southwest France: seizures in elderly patients. Ann Neurol 1990 27 : 232 7.
2. Tallis R Hall G Craig I Dean A. How common are epileptic seizures in old age Age Ageing 1991 20 : 442 8.
3. Hauser WA Annegers JF Kurland LT. Prevalence of epilepsy in Rochester, Minnesota: 1940-1980. Epilepsia 1991 32 : 429 45.
4. Hauser WA Annegers JF Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester. Minnesota: 1935-1984. Epilepsia 1993 34 : 453 68.
5. Wallace H Shorvon S Tallis R. Age-specific incidence and prevalence rates of treated epilepsy in an unselected population of 2,052,922 and age-specific fertility rates of women with epilepsy. Lancet 1998 352 : 1970 3.
6. Hauser WA Annegers JF. Risk factors for epilepsy. Epilepsy Res Suppl 1991 4 : 45 52.
7. Reith J Jorgensen HS Nakayama H Raaschou HO Olsen TS. Seizures in acute stroke: predictors and prognostic significance. The Copenhagen Stroke Study. Stroke 1997 28 : 1585 9.
8. Burn J Dennis M Bamford J Sandercock P Wade D Warlow C. Epileptic seizures after a first stroke: the Oxfordshire Community Stroke Project. BMJ 1997 315 : 1582 7.
9. Cleary P Shorvon S Tallis R. Late-onset seizures as a predictor of subsequent stroke. Lancet 2004 363 : 1184 6.
10. Hesdorffer DC Hauser WA Annegers JF Kokmen E Rocca WA. Dementia and adult-onset unprovoked seizures. Neurology 1996 46 : 727 30.
11. Hauser WA. Seizure disorders: the changes with age. Epilepsia 1992 33 ( Suppl. 4 S6 14.
12. Romanelli MF Morris JC Ashkin K Coben LA. Advanced Alzheimer's disease is a risk factor for late-onset seizures. Arch Neurol 1990 47 : 847 50.
13. NICE (National Institute for Clinical Excellence). Clinical Guideline 20. The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care. London : NICE, 2004.
14. Hart YM Sander JW Johnson AL Shorvon SD. National General Practice Study of Epilepsy: recurrence after a first seizure. Lancet 1990 336 : 1271 4.
15. Ramsay RE Pellock JM Garnett WR et al. Pharmacokinetics and safety of lamotrigine (Lamictal) in patients with epilepsy. Epilepsy Res 1991 10 : 191 200.
16. Carpay JA Aldenkamp AP Van Donselaar CA. Complaints associated with the use of antiepileptic drugs: results from a community-based study. Seizure 2005 14 : 198 206.
17. Aldenkamp AP De Krom M Reijs R. Newer antiepileptic drugs and cognitive issues. Epilepsia 2003 44 ( Suppl. 4 21 9.
18. Eucare (European Concerted Action and Research on Epilepsy). The European White Paper on Epilepsy. Epilepsia 2003 44 ( Suppl. 6 1 88.
19. Dreifuss FE. Valproate toxicity. In : Levy RH Mattson RH Meldrum BS, eds. Antiepileptic drugs, 4th edn. New York : Raven Press, 1995 641 8.
20. Armon C Shin C Miller P et al. Reversible parkinsonism and cognitive impairment with chronic valproate use. Neurology 1996 47 : 626 35.
21. Sheth RD Wesolowski CA Jacob JC et al. Effect of carbamazepine and valproate on bone mineral density. J Pediatr 1995 127 : 256 62.
22. Sato Y Kondo I Ishida S et al. Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy. Neurology 2001 57 : 445 9.
23. Bender AD. Effect of age on intestinal absorption: implications for drug absorption in the elderly. J Am Geriatr Soc 1968 16 : 1331 9.
24. Birnbaum A Hardie NA Leppik IE et al. Variability of total phenytoin serum concentrations within elderly nursing home residents. Neurology 2003 60 : 555 9.
25. Forbes GB Reina JC. Adult lean body mass declines with age: some longitudinal observations. Metabolism 1970 19 : 653 63.
26. Hammerlein A Derendorf H Lowenthal DT. Pharmacokinetic and pharmacodynamic changes in the elderly. Clinical implications. Clin Pharmacokinet 1998 35 : 49 64.
27. Perucca E Grimaldi R Gatti G Pirracchio S Crema F Frigo GM. Pharmacokinetics of valproic acid in the elderly. Br J Clin Pharmacol 1984 17 : 665 9.
28. Bauer LA Davis R Wilensky A Raisys V Levy RH. Valproic acid clearance: unbound fraction and diurnal variation in young and elderly adults. Clin Pharmacol Ther 1985 37 : 697 700.
29. Baruzzi A Contin M Perucca E Albani F Riva R. Altered serum protein binding of carbamazepine in disease states associated with an increased alpha 1-acid glycoprotein concentration. Eur J Clin Pharmacol 1986 31 : 85 9.
30. Bachmann KA Belloto RJ Jr. Differential kinetics of phenytoin in elderly patients. Drugs Aging 1999 15 : 235 50.
31. Battino D Croci D Mamoli D Messina S Perucca E. Influence of aging on serum phenytoin concentrations: a pharmacokinetic analysis based on therapeutic drug monitoring data. Epilepsy Res 2004 59 : 155 65.
32. Cloyd JC Lackner TE Leppik IE. Antiepileptics in the elderly. Pharmacoepidemiology and pharmacokinetics. Arch Fam Med 1994 3 : 589 98.
33. Battino D Croci D Rossini A Messina S Mamoli D Perucca E. Serum carbamazepine concentrations in elderly patients: a case-matched pharmacokinetic evaluation based on therapeutic drug monitoring data. Epilepsia 2003 44 : 923 9.
34. Messina S Battino D Croci D Mamoli D Ratti S Perucca E. Phenobarbital pharmacokinetics in old age: a case-matched evaluation based on therapeutic drug monitoring data. Epilepsia 2005 46 : 372 7.
35. Wynne HA Cope LH Mutch E Rawlins MD Woodhouse KW James OF. The effect of age upon liver volume and apparent liver blood flow in healthy man. Hepatology 1989 9 : 297 301.
36. Bach B Hansen JM Kampmann JP Rasmussen SN Skovsted L. Disposition of antipyrine and phenytoin correlated with age and liver volume in man. Clin Pharmacokinet 1981 6 : 389 96.
37. Sotaniemi EA Arranto AJ Pelkonen O Pasanen M. Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions. Clin Pharmacol Ther 1997 61 : 331 9.
38. Mclean AJ Le Couteur DG. Aging biology and geriatric clinical pharmacology. Pharmacol Rev 2004 56 : 163 84.
39. Perucca E. Clinical pharmacokinetics of new generation antiepileptic drugs at the extremes of age. Clin Pharmacokinet 2006 45 : 351 63.
40. Tateishi T Fujimura A Shiga T Ohashi K Ebihara A. Influence of aging on the oxidative and conjugative metabolism of propranolol. Int J Clin Pharmacol Res 1995 15 : 95 101.
41. Van Heiningen PN Eve MD Oosterhuis B et al. The influence of age on the pharmacokinetics of the antiepileptic agent oxcarbazepine. Clin Pharmacol Ther 1991 50 : 410 9.
42. Posner J Holdich T Crome P. Comparison of lamotrigine pharmacokinetics in young and elderly healthy volunteers. J Pharm Med 1991 1 : 121 8.
43. Friedman SA Raizner AE Rosen H Solomon NA Sy W. Functional defects in the aging kidney. Ann Intern Med 1972 76 : 41 5.
44. Davies DF Shock NW. Age changes in glomerular filtration rate, effective renal plasma flow, and tubular excretory capacity in adult males. J Clin Invest 1950 29 : 496 507.
45. Spina E Perucca E Levy R. Predictability of metabolic antiepileptic drug interactions. In : Majkowski J Bourgeois BFD Patsalos PN Mattson RH, eds. Antiepileptic drugs: combination therapy and interactions. Cambridge : Cambridge University Press, 2005 57 92.
46. Patsalos PN Perucca E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol 2003 2 : 347 56.
47. Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol 2006 61 : 246 55.
48. Patsalos PN Perucca E. Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol 2003 2 : 473 81.
49. Greenblatt DJ Shader RI Harmatz JS. Implications of altered drug disposition in the elderly: studies of benzodiazepines. J Clin Pharmacol 1989 29 : 866 72.
50. Cameron H Macphee GJ. Anticonvulsant therapy in the elderly - a need for placebo controlled trials. Epilepsy Res 1995 21 : 149 57.
51. Perucca E. Is there a role for therapeutic drug monitoring of new anticonvulsants Clin Pharmacokinet 2000 38 : 191 204.
52. Bergey GK. Initial treatment of epilepsy: special issues in treating the elderly. Neurology 2004 63 : S40 8.
53. Mattson RH Cramer JA Collins JF. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. The Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group. N Engl J Med 1992 327 : 765 71.
54. Bourgeois BFD. Valproic acid. Clinical efficacy and use in epilepsy. In: Levy RH, Mattson RH, Meldrum BS, Perucca E, eds. Antiepileptic drugs, 5th edn. Philadelphia: Lippincott, Williams and Wilkins, 2002 808 17.
55. Marson AG Williamson PR Clough H Hutton JL Chadwick DW. Carbamazepine versus valproate monotherapy for epilepsy: a meta-analysis. Epilepsia 2002 43 : 505 13.
56. Rowan AJ Ramsay RE Collins JF et al. New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine. Neurology 2005 64 : 1868 73.
57. Brodie MJ Overstall PW Giorgi L. Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Res 1999 37 : 81 7.